Kilitch Drugs (India) Limited (IN:KILITCH)
:KILITCH
Want to see IN:KILITCH full AI Analyst Report?
Top Page
Kilitch Drugs (India) Limited
(KILITCH)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹179.00
▼(-49.66% Downside)
Action:Reiterated
Date:05/19/26
The score is held back primarily by weak cash generation (persistent negative free cash flow and deterioration in 2026) despite solid revenue growth and improved profitability. Technically, momentum is positive over shorter timeframes (above 20/50/100-day averages with positive MACD), while valuation appears reasonable with a ~14 P/E.
Positive Factors
Revenue growth
Sustained multi-year revenue scaling indicates expanding commercial footprint and broader product adoption across markets. This durable top-line expansion supports economies of scale, strengthens bargaining power with suppliers, and funds capacity, R&D or geographic expansion over the medium term.
Negative Factors
Negative free cash flow
Persistent and worsening negative free cash flow, especially the sharp ~-806M in 2026, indicates weak cash conversion from operations or heavy capex/working-capital deployment. This creates structural funding risk, likely requiring continued external financing and raising long-term cost of capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth
Sustained multi-year revenue scaling indicates expanding commercial footprint and broader product adoption across markets. This durable top-line expansion supports economies of scale, strengthens bargaining power with suppliers, and funds capacity, R&D or geographic expansion over the medium term.
Read all positive factors
Kilitch Drugs (India) Limited (KILITCH) vs. iShares MSCI India ETF (INDA)
Market Cap
₹6.39B
Dividend YieldN/A
Average Volume (3M)2.19K
Price to Earnings (P/E)7.3
Beta (1Y)0.80
Revenue Growth18.74%
EPS Growth11.32%
CountryIN
Employees168
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)8.39
Shares Outstanding34,961,563
10 Day Avg. Volume2,304
30 Day Avg. Volume2,185
Financial Highlights & Ratios
PEG Ratio1.44
Price to Book (P/B)1.51
Price to Sales (P/S)1.79
P/FCF Ratio-5.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.5
Revenue Forecast (FY)₹2.64B
Kilitch Drugs (India) Limited Business Overview & Revenue Model
Company Description
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malaria...
How the Company Makes Money
Kilitch Drugs (India) Limited primarily makes money by selling pharmaceutical products (drug formulations) to customers in India and overseas. Its revenue model is based on: (1) Product sales: income from the manufacture and sale of finished formu...
Kilitch Drugs (India) Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
71
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.09B | 2.35B | 1.98B | 1.54B | 1.40B | 1.14B |
| Gross Profit | 951.14M | 914.13M | 937.39M | 731.38M | 624.64M | 337.44M |
| EBITDA | 446.60M | 366.00M | 426.26M | 287.43M | 206.50M | 134.13M |
| Net Income | 275.76M | 301.66M | 267.01M | 146.01M | 104.48M | 73.67M |
Balance Sheet | ||||||
| Total Assets | 3.99B | 4.58B | 3.13B | 2.40B | 2.20B | 2.10B |
| Cash, Cash Equivalents and Short-Term Investments | 870.13M | 687.39M | 593.98M | 690.19M | 591.77M | 572.43M |
| Total Debt | 836.13M | 887.09M | 494.24M | 316.46M | 221.94M | 204.32M |
| Total Liabilities | 1.34B | 1.81B | 1.12B | 643.88M | 689.41M | 695.55M |
| Stockholders Equity | 2.66B | 2.80B | 2.02B | 1.76B | 1.52B | 1.39B |
Cash Flow | ||||||
| Free Cash Flow | -581.23M | -805.64M | -293.31M | -65.97M | -12.26M | -24.19M |
| Operating Cash Flow | -66.20M | 189.43M | 175.42M | -1.46M | 25.86M | 57.83M |
| Investing Cash Flow | -514.49M | -1.01B | -399.47M | -95.45M | 79.15M | -152.50M |
| Financing Cash Flow | 813.60M | 880.13M | 132.43M | 88.07M | -7.16M | 70.28M |
Kilitch Drugs (India) Limited Technical Analysis
Positive
355.60
Price Trends
151.57
Positive
159.58
Positive
172.89
Positive
Market Momentum
8.28
Negative
69.44
Neutral
82.91
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KILITCH, the sentiment is Positive. The current price of 355.6 is above the 20-day moving average (MA) of 160.62, above the 50-day MA of 151.57, and above the 200-day MA of 172.89, indicating a bullish trend. The MACD of 8.28 indicates Negative momentum. The RSI at 69.44 is Neutral, neither overbought nor oversold. The STOCH value of 82.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:KILITCH.
Kilitch Drugs (India) Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | ₹6.39B | 7.34 | ― | ― | 18.74% | 11.32% | |
60 Neutral | ₹5.36B | 19.82 | ― | ― | -1.22% | -52.32% | |
55 Neutral | ₹4.01B | -3.91 | ― | 0.66% | -3.52% | -108.70% | |
55 Neutral | ₹3.63B | 56.53 | ― | 0.26% | -7.50% | 6.39% | |
54 Neutral | ₹4.25B | -100.74 | ― | ― | 78.04% | -16.99% | |
52 Neutral | ₹2.72B | 7.63 | ― | ― | -57.41% | -2188.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:KILITCH
Kilitch Drugs (India) Limited
182.90
-46.02
-20.10%
IN:ALBERTDAVD
Albert David Ltd
702.90
-101.79
-12.65%
IN:MEDICAMEQ
Medicamen Biotech Limited
267.75
-161.06
-37.56%
IN:NECLIFE
Nectar Lifesciences Ltd.
12.11
-12.94
-51.66%
IN:VALIANTLAB
Valiant Laboratories Ltd.
78.19
-16.48
-17.41%
IN:ZIMLAB
Zim Laboratories Ltd.
100.04
8.84
9.69%
Kilitch Drugs (India) Limited Corporate Events
Kilitch Drugs files SEBI dematerialisation compliance certificate for March quarter
Apr 14, 2026
Kilitch Drugs (India) Limited has submitted to the stock exchanges a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31 March 2026. The certificate, issued by its r...
Kilitch Drugs Closes Trading Window Ahead of FY26 Results
Mar 25, 2026
Kilitch Drugs (India) Limited has announced that its trading window for dealing in the company’s securities will be closed for all designated persons and their immediate relatives from April 1, 2026. This restriction will remain in place unt...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.